Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome

[1]  M. Hickey,et al.  Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration , 2017, Scientific Reports.

[2]  R. Mittler,et al.  GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome. , 2016, The Journal of clinical endocrinology and metabolism.

[3]  M. Krass,et al.  Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1 , 2016, Journal of diabetes research.

[4]  F. Urano.  Wolfram Syndrome: Diagnosis, Management, and Treatment , 2016, Current Diabetes Reports.

[5]  T. Vilsbøll,et al.  Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia , 2016, Journal of internal medicine.

[6]  Shuyi Cao,et al.  Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets , 2015, International journal of molecular medicine.

[7]  S. Seino,et al.  Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice , 2015, PloS one.

[8]  P. Wang,et al.  Diabetes mellitus—advances and challenges in human β-cell proliferation , 2015, Nature Reviews Endocrinology.

[9]  G. Rutter,et al.  Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia , 2014, PloS one.

[10]  J. Holst,et al.  Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals , 2014, Diabetologia.

[11]  L. Schalkwyk,et al.  Effect of Chronic Valproic Acid Treatment on Hepatic Gene Expression Profile in Wfs1 Knockout Mouse , 2014, PPAR research.

[12]  Mitsunori Matsumae,et al.  Neuroprotective Effects of Liraglutide for Stroke Model of Rats , 2013, International journal of molecular sciences.

[13]  T. Rabelink,et al.  Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice , 2013, Diabetologia.

[14]  Hongli Zhang,et al.  Liraglutide protects pancreatic beta cells during an early intervention in Gato‐Kakizaki rats (Gato‐Kakizaki大鼠使用利拉鲁肽进行早期干预可以保护胰腺β细胞) , 2013, Journal of diabetes.

[15]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[16]  J. Ayala,et al.  Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. , 2013, American journal of physiology. Cell physiology.

[17]  P. Chambon,et al.  PPARβ/δ affects pancreatic β cell mass and insulin secretion in mice. , 2012, The Journal of clinical investigation.

[18]  B. Hering,et al.  Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB. , 2012, Endocrinology.

[19]  S. Kõks,et al.  Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin , 2011, Journal of Physiology and Biochemistry.

[20]  A. Dobrian,et al.  Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. , 2011, American journal of physiology. Endocrinology and metabolism.

[21]  V. Tillmann,et al.  Sex differences in the development of diabetes in mice with deleted wolframin (Wfs1) gene. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[22]  C. Nunemaker,et al.  A Practical Guide to Rodent Islet Isolation and Assessment , 2009, Biological Procedures Online.

[23]  T. Vilsbøll.  The effects of glucagon‐like peptide‐1 on the beta cell , 2009, Diabetes, obesity & metabolism.

[24]  H. Ellingsgaard,et al.  Increased Number of Islet-Associated Macrophages in Type 2 Diabetes , 2007, Diabetes.

[25]  B. Yusta,et al.  GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress , 2006 .

[26]  Y. Zhang,et al.  Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. , 2006, Cell metabolism.

[27]  B. Yusta,et al.  GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. , 2006, Cell metabolism.

[28]  Sachi Kato,et al.  Morphological analysis of ghrelin and its receptor distribution in the rat pancreas , 2005, Regulatory Peptides.

[29]  A. Astrup,et al.  The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. , 2004, Diabetes care.

[30]  H. Katagiri,et al.  Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. , 2004, Human molecular genetics.

[31]  Jeppe Sturis,et al.  One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. , 2004, Diabetes.

[32]  T. Barrett,et al.  DIDMOAD syndrome; further studies and muscle biochemistry , 1995, Journal of Inherited Metabolic Disease.

[33]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[34]  P. Behn,et al.  A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome) , 1998, Nature Genetics.

[35]  T. Barrett,et al.  Wolfram (DIDMOAD) syndrome. , 1997, Journal of medical genetics.

[36]  M. Mcdaniel,et al.  Cytokines and Nitric Oxide in Islet Inflammation and Diabetes , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[37]  X. Remesar,et al.  Rat insulin turnover in vivo. , 1995, Endocrinology.

[38]  S. Bonner-Weir,et al.  Dynamics of β-cell Mass in the Growing Rat Pancreas: Estimation With a Simple Mathematical Model , 1995, Diabetes.

[39]  C. Greenbaum,et al.  Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. , 1991, The Journal of clinical investigation.

[40]  R. Unger,et al.  Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. , 1987, The Journal of clinical investigation.

[41]  A. Katz,et al.  Metabolism of proinsulin, insulin, and C-peptide in the rat. , 1973, The Journal of clinical investigation.